The PLCG2 antibody targets phospholipase C gamma 2 (PLCG2), a key enzyme in intracellular signaling pathways, particularly within immune cells. PLCG2 is a member of the phospholipase C family, which hydrolyzes phosphatidylinositol 4.5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1.4.5-trisphosphate (IP3), critical secondary messengers regulating calcium release and protein kinase C (PKC) activation. Expressed predominantly in hematopoietic cells, PLCG2 plays a vital role in B-cell receptor (BCR) and Fc receptor (FcR) signaling, influencing immune responses, cell proliferation, and differentiation.
PLCG2 contains distinct domains, including SH2. SH3. and catalytic regions, enabling interactions with tyrosine-phosphorylated proteins like Syk and receptor tyrosine kinases. Dysregulation of PLCG2 is linked to immune disorders. Gain-of-function mutations are associated with autoinflammatory diseases (e.g., PLAID, APLAID), while loss-of-function variants may contribute to immunodeficiency.
PLCG2 antibodies are essential tools for studying its expression, activation, and localization in immune cells. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate its role in pathological mechanisms or therapeutic targeting. Research on PLCG2 antibodies also aids in developing diagnostic biomarkers and tailored therapies for immune-related conditions.